Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

JAYS on Summer Tour with Låt Live Leva

General Press Release JAYS are one of the main sponsors of the Låt Live Leva 2020 Summer Tour. Låt Live Leva is an initiative to support artists, musicians and the Swedish live-scene. Due to Covid-19 tours and concerts have been cancelled and the music industry have suffered. This summer Låt Leva Live will visit several Swedish cities for a summer happening to remember! The aim with the festival is to support the music industry and at the same time create a great local happening. Since Corona emerged Låt Leva Live have been touring in Stockholm, Umeå, Uppsala and Malmö and viewed by

Insr: Notification from the Norwegian Financial Supervisory Authority (NFSA) and Announcement of Strategic Review

Oslo, June 29, 2020 Insr, on Friday after market close, received a notification where the NFSA considers withdrawing the license to operate due to unresolved risk and control issues. The company is in the process of implementing a further strengthening of the governance, risk and control structure. The Board of Directors has decided to initiate a strategic review to explore the alternatives available to the company. In connection with this, the private placement announced on June 25th will not be completed, although it was oversubscribed by existing and new shareholders. The

Swedish healthcare region to realize integrated diagnostics—expands IT solution from Sectra with digital pathology

Linköping, Sweden – June 29, 2020 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) has signed a digital pathology contract with Region Västmanland in Sweden. The healthcare region already uses Sectra’s software for handling medical images, which will now be expanded to also include digital pathology as it digitizes its pathology department. Using the same system to store and view images and information from various diagnostic specialties enables integrated diagnostics, which is key for efficient cancer care.“We are excited to take the

Altor acquires a minority stake in renewables developer OX2

Altor Fund V (“Altor”) has signed an agreement to acquire a 30% stake in OX2 AB (“OX2”) and to enter a partnership with Peas Industries AB (“Peas Industries”). Altor will support the company on its continued growth journey and to continue lead the shift to renewable energy in Europe. The founders through Peas Industries will remain as majority shareholders and continue to stay active in the development of OX2.OX2 is a leading European renewables development company. Founded in 2004 OX2 has grown to become the #1 independent developer in Europe having realised more than 2.4 GW of wind power.

BioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease

Stockholm, Sweden, June 29, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they have signed a research collaboration agreement to increase the understanding of Apolipoprotein E (ApoE) as a drug target for Alzheimer’s disease. BioArctic will provide financial support for a two-year research position, with potential extension, and Professor Lars Nilsson at the Department of Pharmacology will be heading the research project at University of Oslo.      Apolipoprotein E is the major genetic risk factor

BioStock Studio: Scandion Oncology pushes forward with confidence

Scandion Oncology has been very active of late, which has had significant effect on the company share. BioStock was happy to welcome CEO Nils Brünner back to the BioStock studio to give us some background about the company and discuss what makes Scandion Oncology an attractive investment.Watch the video interview with Scandion Oncology's CEO Nils Brünner at biostock.se : https://www.biostock.se/en/biostock-studio-scandion-oncology-pushes-forward-with-confidence/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

DERMATOLOGY HIFU PRODUCT RELEASE

TOOsonix CE marks and releases new medical ultrasonic device for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions.Hoersholm, Denmark, June 29[th] 2020 - TOOsonix A/S, a pioneer in HIFU focused ultrasound technology for dermatology, today announce that it has released its System ONE-M as a CE-marked medical device for aesthetic treatments. The release coincides with the publication of two clinical papers in the peer-reviewed scientific journal, Skin Research and Technology (John Wiley and Sons, Inc.), describing very

Flexion Mobile publishes its annual report for the financial year 2019/2020

LONDON, 29th of June, 2020 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today published its annual report for the financial year ending March 2020. If you would like to order a copy of the report, please send an e-mail with your name and address to ir@ (ir@stillfront.com)flexionmobile.com. Words from the CEO:   "The last few months have been incredibly busy and I want to particularly thank my finance team for managing to get this annual report produced and audited during the pandemic considering that many UK companies have asked for an extension.

ASSA ABLOY sells certain businesses in relation to the acquisition of agta record

ASSA ABLOY has entered into binding agreements with Italy based FAAC Group for the sale of certain agta record and ASSA ABLOY businesses, as part of the commitments to address the competition concerns of the EU Commission in connection with the acquisition of the Swiss company agta record (the “Divestiture”). The divested business includes the agta record operations in the Netherlands, Austria, Hungary and Slovenia, as well as the ASSA ABLOY automatic pedestrian door business in France and the UK. In addition, agta record´s high-speed door business located in France is also included.

NENT Group’s esports comedy ‘Try Hard’ is next original Danish series

· Eight-part comedy created by Anders Morgenthaler (‘Princess’) and Allan Hyde (‘True Blood’) · ‘Try Hard’ to premiere on Viaplay in autumn 2020 · NENT Group to premiere at least 30 original productions in 2020 The Danish esports-focused series ‘Try Hard’ is the next original production from Nordic Entertainment Group (NENT Group), the Nordic region’s leading streaming company. Created by Danish director and artist Anders Morgenthaler (‘Princess’) with Allan Hyde (‘True Blood’), the eight-episode comedy tells the story of the increasingly questionable efforts of five young gamers

SBB initiates a collaboration with Odalen Fastigheter - builds elderly care home in Ängelholm and prepares for new construction in Gothenburg

Samhällsbyggnadsbolaget I Norden AB (“SBB”) initiates a collaboration with Odalen Fastigheter AB (“Odalen Fastigheter”)  through a joint-venture company to scale up new construction of community service properties with a focus mainly on elderly care homes. The joint-venture company is already building an elderly care home in Ängelholm (a growing city located in the south of Sweden) and is preparing for new construction in Gothenburg. In connection with its Capital Markets Day earlier in June, SBB highlighted its large building rights portfolio and the new focus on using the building

Peab builds top modern swimming pool facility in Kiruna

Peab has been commissioned to build a new swimming pool facility in the new Kiruna City Center. The customer is Kiruna Municipality through WeGroup EPCM Projekt and the contract is worth SEK 290 million.The new facility, which will replace Kiruna’s existing swimming pool, will be two stories high for a total of 10,500 m2 and contain all of 14 pools. The pools will run from two 25 meter exercise pools to multi-pools that have height adjustable bottoms to play pools to family pools. The new swimming pool facility will also have a relax section with a lounge area, warm and cold pools and a so-

Invitation to Kungsleden’s presentation of interim report for January–June 2020

On Wednesday, 8 July 2020, at 7:00 a.m. (CEST), Kungsleden AB (publ) will publish its interim report for January–June 2020. The interim report will be presented via telephone conference and audio broadcast at 8:45 a.m. (CEST)Kungsleden invites investors, asset managers, financial analysts and the press to a presentation of the interim report, where CEO Biljana Pehrsson and Deputy CEO/CFO Ylva Sarby Westman will comment on the report. The report will be published at 7:00 a.m. and will be available to download at https://www.kungsleden.se/en/investors/reports-and-presentations/

Mentice receives order of total SEK 6.0 million from Abbott EP

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from Abbott EP for the segment Medical Device Industry. The order covers system sales and development to be delivered during the third quarter 2020. The total order value amounts to SEK 6.0 million and will be accounted for in the order book for the second quarter 2020. The order covers development of additional functionality and the delivery of a global fleet of ultraportable simulators for internal and physician education to be

Orkla ASA: Invitation to presentation of Orkla’s second quarter 2020 results, Monday 13 July

Orkla will report its second quarter 2020 results on Monday, 13 July 2020 at 7.00 a.m. CET. The quarterly report and the presentation material will be available at this time at www.orkla.com.The results will be presented in a webcast with Presidet & CEO Jaan Ivar Semlitsch and CFO Harald Ullevoldsæter at 8.00 a.m. CET. As a consequence of the Corona situation, there will not be a physical presentation of the results. The presentation and subsequent Q&A session will be held in English and may be viewed live at www.orkla.com (direct link: https://events.webcast.no/orkla-asa/

Annual result 2019: Strong growth and a larger geographic footprint

June 29, 2020: 2019 was a strong year for GlobalConnect. The company announced a merger with IP-Only, expanded the fiber network to a total of 74,500 km and invested in services enabling value-adding services such as SD-WAN and managed LAN. The new GlobalConnect/IP-Only group had a total revenue* of 547 million EUR in 2019 whilst investing 381 million EUR.During 2019, GlobalConnect has invested in network and solutions to strengthen its position as the number one challenger offering end-to-end connectivity solutions to businesses and consumers across Northern Europa. From 2020, the combined

SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome

SynAct Pharma AB ("SynAct") today announced that the company has initiated a Phase II clinical study with the AP1189 compound in idiopathic membranous nephropathy patients with Nephrotic Syndrome.In the Phase IIa study, AP1189 will be tested in a double-blind, placebo-controlled multicentre study as add-on therapy to ACE-inhibitor or Angiotensin-2 receptor antagonists in a once-daily dose regimen for four weeks with the primary purpose to show treatment effect on urinary protein excretion relative to pre-treatment levels and placebo. The patients will be dosed with either 100 mg AP1189 or

Planmeca decreases patient doses for 3D images of the head – algorithms provide more detailed imaging and diagnostics

Planmeca has developed smart technologies that help decrease the amount of radiation required to produce medical images without compromising the diagnostic quality of the images. The algorithms developed for 3D imaging help produce more detailed images and diagnostics than ever before.Low-dose imaging is beneficial for any patient, but it is particularly significant for children, as a child’s body has comparably more radiation-sensitive red bone marrow than the body of an adult. When new scientific studies on the subject were published around a decade ago, Planmeca began to develop its

MPC Container Ships ASA announces extraordinary general meeting

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.Oslo, 29 June 2020 Notice of extraordinary general meeting: MPC Container Ships ASA (the "Company") hereby calls for an extraordinary general meeting in the Company to be held on 13 July at 12:00 hours (CEST) by electronic means. The notice is

Skanska builds school in Lund, Sweden, for SEK 630 M

Skanska has signed a contract with the municipality of Lund to build the Hedda Anderssongymnasiet in Lund. The contract is worth SEK 630 M, which will be included in the order bookings for Sweden for the second quarter 2020.Hedda Anderssongymnasiet is a high school that will seat 2,200 students. The building has a total area of approximately 25,000 square meters and will be four floors high. Construction will begin in late June 2020 by demolition of the current school. The new school is scheduled for completion in the second quarter of 2023. Skanska is one of the leading development-

Nordic Nanovector’s Betalutin® Receives Fast-Track Designation from US FDA for Marginal Zone Lymphoma

Oslo, Norway, 29 June 2020 Nordic Nanovector ASA (OSE: NANO) today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin® ([177]Lu lilotomab satetraxetan) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior systemic therapies. Nordic Nanovector is evaluating the opportunity to develop Betalutin® as a single-agent treatment for MZL, a rare type of non-Hodgkin’s lymphoma (NHL). Betalutin® has demonstrated a very promising clinical effect in nine

Atea earns platinum-level award for sustainability

Atea ASA (OSE stock ticker: ATEA) has been awarded the highest rating in environmental and social performance by EcoVadis, a highly respected evaluator of supplier sustainability. This achievement ranks Atea in the top 1% of all suppliers evaluated under a collaborative platform used by more than 65,000 companies today. This latest achievement follows after Atea earned for three successive years EcoVadis’s gold-level ranking. To rate and monitor supplier sustainability, EcoVadis assesses corporate social-responsibility performance, covering 150 purchasing categories in 110 countries. Its

Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms

Press Release June 29,2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms  · Oblique Therapeutics and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot[TM] technology platforms · ONCOS will be used to deliver Abiprot[TM] antibodies against hard-to-reach targets such as mutant RASGothenburg, Sweden & Oslo, Norway,June 29 2020 – Oblique Therapeutics today announces that it has entered into a collaboration agreement with Targovax ASA (OSE: TRVX)

Targovax and Oblique enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms

· Targovax and Oblique will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot technology platforms · ONCOS will be used to deliver Abiprot antibodies against hard-to-reach targets such as mutant RAS Oslo, Norway, & Gothenburg, Sweden 29 June 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that it has entered into a collaboration agreement with Oblique Therapeutics to evaluate the potential of using ONCOS oncolytic adenoviruses as a

There are no items matching the current filter
There are no more items matching the current filter
Back to top